md-medicaldata

Authors

 

Momčilo Vujetić¹, Janko Janković<sup>2

1</sup>Centar za informatiku i biostatistiku u zdravstvu, Gradski zavod za javno zdravlje, Beograd, Srbija
²Institut za socijalnu medicinu, Medicinski fakultet, Univerzitet u Beogradu, Beograd, Srbija

 

The paper was received on 12.05.2017/ Accepted on. 30.05.2017.

 

Correspondence to

Doc. dr Janko Janković,
Institut za socijalnu medicinu, Dr Subotića 15,
Medicinski fakultet, Univerzitet u Beogradu,
11000 Beograd, Srbija;
e-mail: drjankojankovic@yahoo.com
tel.: +381 11 2643830

 

 

Abstract

 

Introduction: Cancer is the second leading causes of morbidity and mortality worldwide and in our country. The aim of this study was to calculate cancer incidence rates in Belgrade population in the period of 2005-2014 and to examine the trend in the reporting period. Method: Descriptive epidemiological method was used. Data on cancer morbidity were obtained from the Register of persons suffering from diseases of major public health importance of the Belgrade's Public Health Institute. Crude, standardized and age-specific cancer incidence rates per 100,000 inhabitants were calculated for the ten-year period from 2005 to 2014. To assess the trends of cancer morbidity during the observed period linear regression analyses were used. Results: In Belgrade during the period from 2005 to 2014 a total of 108,636 persons suffering from malignant neoplasms were registrated. Cancer standardized incidence rates for the city of Belgrade were higher in men compared to women for each single year in the examined period. During that period, in both sexes, statistically significant trend in standardized incidence rates was not observed (men: y=369.237+4.493x, p=0,377; women: y=316.430+4.908x, p=0,264). The mean value of standardized incidence rate of lung cancer in men (67.1 per 100,000) was 1.4 times higher than the incidence rate of colorectal cancer (47.1 per 100,000), and 1.7 times higher than the incidence rate of prostate cancer ( 38.7 per 100,000). Standardized incidence rates for the three most common malignant neoplasms in women showed that the average standardized incidence rate of breast cancer (82.7 per 100,000) is 3.0 times higher than the rate of colorectal cancer (27.5 per 100,000), and 3.8 times higher than the rate of lung cancer (25.2 per 100,000) Conclusion: Cancer morbidity in ten-year period in Belgrade has been increased. Primary prevention measures like smoking cessation, healthy diet and regular physical activity are recommnended. For the early detection of malignant neoplasms it is necessary to perform screening for breast, colorectal, and cervical cancer, which is in the domain of secondary cancer prevention.

 

 

 

Key words:

cancers, incidence, trend, Belgrade

 

 

Sažetak

 

Uvod: Maligni tumori, posle kardiovaskularnih bolesti, predstavljaju najčešći uzrok obolevanja i umiranja ljudi, kako u svetu, tako i u našoj zemlji. Cilj rada je da se izračunaju stope incidencije od malignih bolesti u beograskoj populaciji u periodu od 2005. do 2014. godine i da se ispita njihov trend kretanja u posmatranom periodu. Metod: U studiji je korišćena deskriptivna epidemiološka metoda. Podaci o morbiditetu od malignih bolesti su dobijeni iz Registra lica obolelih od bolesti od većeg javno-zdravstvenog značaja Gradskog zavoda za javno zdravlje Beograd. Izračunate su sirove, standardizovane i uzrasno specifične stope incidencije od malignih tumora na 100.000 stanovnika, za period od 2005. do 2014. godine. Za procenu trendova obolevanja od malignih tumora tokom posmatranog perioda koristili smo linearnu regresionu analizu. Rezultati: U periodu od 2005. do 2014. godine u Beogradu je registrovano ukupno 108.636 lica obolelih od malignih neoplazmi. Standardizovane stope incidencije od malignih bolesti za grad Beograd su veće kod muškaraca nego kod žena za svaku pojedinačnu godinu u ispitivanom periodu. Tokom posmatranog perioda, kod osoba oba pola nije zapažen statistički značajan trend u standardizovanim stopama incidencije (muškarci: y=369,237+4,493x, p=0,377; žene y=316,430+4,908x, p=0,264). Srednja vrednost standardizovane stope incidencije od malignog tumora pluća kod muškaraca (67,1 na 100.000) bila je 1,4 puta veća od stope incidencije od malignog tumora kolorektuma (47,1 na 100.000), i 1,7 puta veća od stope incidencije od malignog tumora prostate (38,7 na 100.000). Standardizovane stope incidencije od 3 najčešća maligna tumora kod žena po godinama pokazuju da je srednja vrednost standardizovane stope incidencije od malignih tumora dojke (82,7 na 100.000) 3 puta veća od stope od malignog tumora kolorektuma (27,5 na 100.000), i 3,8 puta veća od stope od malignog tumora pluća (25,2 na 100.000). Zaključak: Obolevanje od malignih bolesti u desetogodišnjem periodu posmatranja u beogradskoj populaciji se povećalo. Kao mere primarne prevencije preporučuju se prestanak pušenja cigareta, pravilna ishrana i redovna fizička aktivnost. Radi što ranijeg otkrivanja malignih bolesti potrebno je raditi skrininge za rak dojke, rak kolona i rak grlića materice, što spada u domen sekundarne prevencije malignih tumora.

 

 

Ključne reči:

maligni tumori, incidencija, trend, Beograd

 

 

References

 

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74–108.
2. WHO. Globocan 2012: Estimated cancer incidence, mortality and prevalence. Dostupno na: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (pristupljeno 3. februara 2017)
3. Institut za javno zdravlje Srbije. Incidencija i mortalitet od raka u centralnoj Srbiji, 2013. Beograd: Institut za javno zdravlje; Izvestaj broj 15, 2015.
4. Nacionalni program ”Srbija protiv raka” - Ministarstvo zdravlja RS. Dostupno na http://www.zdravlje.gov.rs (pristupljeno 3. februara 2017)
5. WHO. Resolutions and decisions. WHА 58.22. Cancer prevention and control. Dostupno na: http://apps.who.int/medicinedocs/documents/s21323en/s21323en.pdf (pristupljeno 3. februara 2017)
6. Segi M. Cancer Mortality for selected sites in 24 Countries (1950–57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
7. Mihajlovic J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. Cancer incidence and mortality in Serbia 1999-2009. BMC Cancer 2013;13:18.
8. Skuladottir H,Olsen JH. Epidemiology of lung cancer. In: Spiro SG, editor. Lung Cancer. European Respiratory Monograph 2001; 6 (monograph 17): 1-11.
9. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990- 2020: Global burden of disease. Lancet 1997;349:1498-504.
10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):359-86.
11. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of the type of tobacco and inhalation pattern to pulmonary and total mortality. Eur Respir J 1992;5(9):1111-7.
12. Schmiegel W, Pox C, Reinacher-Schick A et al.; Federal Committee of Physicians and Health Insurers. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 2010;48(1):65-136.
13. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD. Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of colon cancer. Dis Colon Rectum 2012;55(8):831-43.
14. Odike MA, Dongo AE, Alufohai EF, Odike AI. Colonic cancer in adolescents. A report of three cases. Rare Tumors 2009;1(2):34.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
16. Chan AT, Giovannucci EL. Primary Prevention of Colorectal Cancer. Gastroenterology 2010;138(6):2029-43.
17. ESMO - European Society for Medical Oncology, the leading European professional organisation for medical oncology. Dostupno na: http://www.esmo.org (pristupljeno 3. februara 2017)
18. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys 2015;72(2):333-8.
19. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015;24(10):1495-506.
20. Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol 2016;59(4):651-72.
21. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61(6):1079-92.

UDK: 616-006(497.11)"2005/2014"
COBISS.SR-ID 239030028

PDF Vujetić M. and Janković J. MD-Medical Data 2017;9(2): 089-094